Unitree Robotics Co., Ltd. has successfully passed the listing review by the Shanghai Stock Exchange's listing committee, making it eligible for an initial public offering on the STAR Market.
This development positions the company to potentially become the first publicly traded general-purpose humanoid robotics firm on China's A-share market.
Following regulatory approval, the company and its lead underwriter will submit a final issuance plan. After a standard five-day review period, Unitree can publish its formal prospectus and commence the share offering.
According to the latest prospectus, the IPO involves issuing at least 40.45 million new shares, aiming to raise approximately 4.2 billion yuan.
The funds are earmarked for four key projects: intelligent robotics model R&D, robotics body R&D, new intelligent robotics product development, and the construction of an intelligent robotics manufacturing base.
The company's top ten shareholders collectively hold 71.5% of the equity prior to the IPO.
Founder and Chairman Wang Xingxing is the largest individual shareholder with a 23.82% stake.
The employee incentive platform, Shanghai Yuyi, holds 10.94%. Meituan's affiliated entity, Hanhai Information, is the third-largest shareholder with a 7.61% stake.
Shunwei Capital, whose founding partner is Lei Jun, holds a 4.42% stake through an associated entity.
Other prominent investors in the shareholder registry include Tencent, Alibaba, and Ant Group.
**Rapid Review Process**
The company's IPO application progressed at a notably fast pace, taking only 73 days from the initial submission of the prospectus to the listing committee review meeting.
This speed contrasts with the longer review timelines typical for other high-profile listings.
The exchange issued a follow-up inquiry to the company in May, requesting enhanced risk disclosures related to industry trends, competitive landscape, R&D focus, and technological barriers.
Unitree subsequently revised its prospectus to provide more comprehensive risk warnings, a move seen as aligning with the registration-based system's emphasis on full information disclosure rather than outright approval or denial.
Financial experts note this process reflects the evolving IPO regime, where the primary regulatory focus is ensuring investors are fully informed of potential risks while allowing market demand to determine the success of a listing.
**Strategic Shift Towards Embodied AI**
The company's financials and strategic direction show a significant pivot.
Revenue grew substantially from 159 million yuan in 2023 to 1.71 billion yuan in 2025, with net profit turning positive.
Gross margin also improved significantly over this period.
However, in the first quarter of this year, while revenue continued to grow, net profit declined year-over-year, which the company attributes to increased spending on market expansion and research.
A major strategic shift is evident in the allocation of IPO proceeds, with nearly half the total funds targeted for "intelligent robotics model R&D."
This investment represents a massive increase compared to the company's total R&D expenditure over the past three years, signaling a deep commitment to developing the "brain" for robots.
The company is pursuing dual technical pathways in embodied AI and has recently launched open-source models.
It has also consolidated its efforts into a next-generation model focused on autonomous decision-making and multi-task handling, which has been demonstrated on its G1 humanoid robot platform.
A significant recent development is a collaboration with NVIDIA announced in early June.
The partnership aims to create a new humanoid robot reference design, integrating Unitree's hardware with NVIDIA's computing chips and software.
This move signals NVIDIA's expanding role in setting industry standards for robotics development, while for Unitree, it underscores a strategic transition from primarily being a hardware manufacturer to a key player in the embodied AI ecosystem.
Comments